Rising Antifungal Resistance

The Centres for Disease Control and Prevention (CDC) hosted the 10th Annual Fungal Disease Awareness Week (FDAW) to highlight the growing threat of multidrug-resistant fungal infections, as scientists warn that pathogens such as Candida auris are increasingly resistant to conventional antifungal drugs, raising concerns over the effectiveness of existing treatments.  

• Fungi: These are eukaryotic, heterotrophic organisms that include yeasts, moulds and mushrooms. Unlike plants, they lack chlorophyll and obtain nutrients by secreting extracellular enzymes and absorbing organic matter.  
  • They play a vital role as decomposers, recycling nutrients, while also having applications in food production, biotechnology and pharmaceuticals, such as yeast in fermentation and Penicillium in antibiotic production.  
  • However, certain pathogenic fungi cause fungal infections (mycoses) ranging from superficial diseases such as ringworm and nail infections to severe systemic infections, particularly in immunocompromised individuals.  
• Emergence of Candida auris: Originally reported in 2009, this yeast has become a multidrug-resistant pathogen in ICU facilities, causing severe bloodstream infections with a 30-40% mortality rate. 
  • The studies suggest that global warming puts selective pressure on fungi, allowing heat-tolerant variants to survive the human body’s 37°C temperature. 
• Mechanisms of Drug Resistance: 
  • Gene Duplication: Fungi fight azole drugs by making extra copies of the Erg11 gene, increasing the production of ergosterol to negate the drug’s effect. 
  • Genetic Mutation: Mutations in the Fks1 gene allow pathogens to survive high doses of echinocandin drugs like caspofungin. 
  • The Eagle Effect: At exceptionally high drug doses, fungi activate compensatory pathways to produce massive amounts of chitin (the raw material of the fungal cell wall), allowing them to survive treatment paradoxically. 
• Antifungal Drug Targets: Traditional azoles and polyenes target ergosterol in the fungal cell membrane, while echinocandins target the cell wall.  
  • Over 90% of Indian C. auris isolates are resistant to azoles, and 30% are resistant to polyenes. 
• Healthcare Infrastructure Gap: While 20% of reported hospital infections are fungal, most Indian hospitals lack the capabilities to accurately identify and culture these pathogens. 
• Alternative Approaches: Instead of total eradication, which drives rapid evolution, scientists advocate for combination therapies and targeting less critical molecular pathways to stop disease progression without forcing evolutionary resistance.

Comparison: Fungi vs. Bacteria vs. Viruses